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Postpartum Glucose Testing Rates Following Gestational 
Diabetes Mellitus and Factors Affecting Testing Non-compliance 
from Four Tertiary Centers in Korea
The purpose of this study was to investigate postpartum glucose testing rates in patients 
with gestational diabetes mellitus (GDM) and to determine factors affecting testing non-
compliance in the Korean population. This was a retrospective study of 1,686 patients with 
GDM from 4 tertiary centers in Korea and data were obtained from medical records. 
Postpartum glucose testing was conducted using a 2-hr 75-g oral glucose tolerance, 
fasting glucose, or hemoglobin A1C test. Test results were categorized as normal, pre-
diabetic, and diabetic. The postpartum glucose testing rate was 44.9% (757/1,686 
patients); and of 757 patients, 44.1% and 18.4% had pre-diabetes and diabetes, 
respectively. According to the multivariate analysis, patients with a high parity, larger 
weight gain during pregnancy, and referral from private clinics due to reasons other than 
GDM treatment were less likely to receive postpartum glucose testing. However, patients 
who had pharmacotherapy for GDM were more likely to be screened. In this study, 55.1% 
of patients with GDM failed to complete postpartum glucose testing. Considering the high 
prevalence of diabetes (18.4%) at postpartum, clinicians should emphasize the importance 
of postpartum diabetes screening to patients with factors affecting testing noncompliance. 
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INTRODUCTION
Gestational diabetes mellitus (GDM) is defined as carbohydrate 
intolerance with onset or first recognition of pregnancy (1). The 
prevalence of GDM varies from 2.4% to 22.3% worldwide de-
pending on the population studied and the type of diagnostic 
test employed (2,3); and the prevalence of diabetes mellitus (DM) 
continues to increase worldwide (1,4,5). 
 In Korea, 2% to 5% of all pregnant women reportedly develop 
GDM (6). GDM contributes to maternal and neonatal morbidi-
ty, including gestational hypertensive disorders, fetal macroso-
mia, shoulder dystocia, and cesarean delivery (7,8); it also pro-
duces a significant burden on the economy (9). GDM is also as-
sociated with an increased risk for developing type 2 DM, which 
ranges from 2% to 70% depending on the population being stu-
died and the length of follow-up (10). 
 Lifestyle intervention and medication can be used to prevent 
or delay the development of diabetes in women who have been 
identified early as having a high risk for diabetes (11,12). There-
fore, the early identification of DM risk at postpartum is imper-
ative and can be determined by postpartum glucose screening. 
Consequently, both the American Diabetes Association (7) and 
American College of Obstetricians and Gynecologists (13) rec-
ommend postpartum glucose tolerance testing in women with 
GDM. However, rates of postpartum glucose screening are sub-
optimal, which range from 18% to 57% (14-20). 
 Asian ethnicity is a well-recognized risk factor for the devel-
opment of GDM (21,22) and more likely to complete postpar-
tum glucose screening than Caucasian women (17,23,24). There-
fore, the Asian population is a good candidate to determine clini-
cal and physiological factors that predict and/or contribute to 
postpartum glucose screening compliance. However, studies 
available in the context of postpartum glucose testing compli-
ance include Asians as a minor population. In light of this, the 
present study was conducted to investigate postpartum glucose 
testing rates in patients with GDM and to determine factors af-
fecting testing non-compliance in the Korean population.
MATERIALS AND METHODS
Study population 
This was a retrospective study involving patients with GDM, 
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which was conducted in 4 tertiary centers in Korea between Jan-
uary 1, 2008 and August 31, 2011. Patients who received prena-
tal care and delivered at the 4 tertiary centers were enrolled in 
this study. Patients with pre-gestational diabetes were excluded. 
Information collected
Demographic, medical, and physiological data were gathered 
from the women enrolled in this study. We evaluated the age, 
education level, parity, previous diagnosis of GDM, previous 
delivery of large for gestational age babies, a history of DM in 
first-degree relatives, height and weight during the course of 
pregnancy, gestational age at delivery, pharmacotherapy for 
GDM during pregnancy, complications of pregnancy (i.e., pre-
eclampsia), birth weight, neonatal intensive care, delivery mode, 
and postpartum glucose screening.
 The pre-pregnancy body mass index (BMI) was calculated 
for each patient as the weight in kilograms divided by height in 
square meters. Weight gain was defined as weight at the time of 
admission for delivery minus the pre-pregnancy weight. The 
causes for referral were also obtained from patient medical re-
cords. Patients were classified based on referral cause (i.e., re-
ferral for GDM treatment or for reasons other than GDM treat-
ment).
Diagnosis of GDM
All pregnant women were screened for GDM either at 24-28 
weeks of gestation or entry to prenatal care when risk factors for 
diabetes were present using a 1-hr 50-g oral glucose challenge 
test. Risk factors that contributed to early screening included a 
history of GDM; having a first-degree relative with diabetes; a 
history of having a macrosomic, stillborn, or anomalous infant; 
and a pre-pregnancy BMI > 25 kg/m2 (25).
 Women with glucose levels ≥  140 mg/dL underwent a stan-
dard 3-hr 100-g oral glucose tolerance test. The diagnosis of 
GDM was based on the criteria by Carpenter and Coustan and 
at least 2 out of the following 4 diagnostic criteria had to be ful-
filled: fasting plasma glucose ≥ 95 mg/dL, and 1-, 2-, and 3-hr 
glucose levels of ≥ 180 mg/dL, ≥ 155 mg/dL, and ≥ 140 mg/dL, 
respectively (24).
Management of GDM
Out of the 4 tertiary centers, 3 centers (centers 1, 2, and 3) im-
plemented a multidisciplinary team approach with diverse health-
care professionals (i.e., obstetricians, endocrinologist, and di-
eticians). After the diagnosis of GDM, all patients visited an en-
docrinologist to monitor and control their blood glucose levels. 
However, center 4 used traditional methods where blood glu-
cose was monitored and controlled by obstetricians. All centers 
provided similar care for patients with GDM, including healthy 
dietary practices, weight management, exercise, monitoring 
lifetime risk of diabetes, postpartum glucose screening, and pe-
riodic reevaluation of glucose tolerance. 
Postpartum glucose test
Postpartum glucose testing was conducted using a 2-hr 75-g oral 
glucose tolerance, fasting glucose, or hemoglobin A1C (HbA1C) 
test. Postpartum glucose test results were categorized as normal, 
pre-diabetes (i.e., impaired fasting glucose and/or impaired 
glucose tolerance), and diabetes. The diagnostic criteria for pre-
diabetes and diabetes were based on the American Diabetes 
Association guidelines (26). Diabetes was defined as HbA1C 
level of ≥ 6.5%, fasting glucose level of ≥ 126 mg/dL, 2-hr plas-
ma glucose level of ≥ 200 mg/dL post-75 g glucose challenge, 
or a random plasma glucose level of ≥ 200 mg/dL with symp-
toms (i.e., polyuria, polydipsia, and unexplained weight loss). 
Pre-diabetes was defined as HbA1C level 5.7%-6.4%, fasting glu-
cose level of 100-125 mg/dL (indicating impaired fasting glu-
cose), or a 2-hr glucose level of 140-199 mg/dL post-75 g glucose 
challenge (indicating impaired glucose tolerance).
Statistical analysis
Data were expressed as the mean ± standard deviation for con-
tinuous variables and percentages for categorical variables. Stu-
dent’s t-tests were used to assess the statistical significance be-
tween normally distributed continuous variables. Categorical 
variables were compared using the chi-square test. A model of 
multivariate logistic regression analysis was used to evaluate 
the factors related to postpartum glucose screening non-com-
pliance after adjustment for covariates that had statistical val-
ues of P less than 0.15 in the univariate analysis. Results were 
considered statistically significant when P values were < 0.05 
(two-sided). Statistical analyses were performed using SPSS soft-
ware, version 12.0 (SPSS Inc., Chicago, IL, USA).
Ethics statement
Ethical approval of the study was obtained from the institution-
al review board (KUGH14261-001, 4-2013-0543, KUH1040027, 
2014-11-050-001). The need to obtain informed consent was 
waived.
RESULTS
A total of 1,686 patients with GDM were included during the 
study period. The mean postpartum glucose testing rate was 
44.9% (757/1,686 patients). Based on the oral glucose tolerance 
test results, 172 (31.2%) had prediabetes, and 54 (9.8%) had dia-
betes. Based on the fasting glucose results, 82 (35.5%) had pre-
diabetes, and 6 (2.6%) had diabetes. In contrast, using HbA1C 
test, 165 (43.5%) had prediabetes, and 91 had diabetes (24.0%). 
With the combination of oral glucose tolerance, the fasting glu-
cose and HbA1C test, 334 (44.1%) had prediabetes, and 139 had 
diabetes (18.4%).
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Table 1. Characteristics of women according to postpartum glucose test compliance
Characteristics
Non-compliant 
to postpartum 
test 
(n = 929)
Compliant to 
postpartum 
test 
(n = 757)
P value
Age (yr) 33.76 ± 4.20 33.67 ± 4.13 0.65
Pre-pregnancy BMI (kg/m2) 23.83 ± 4.67 23.66 ± 4.44 0.48
Weight gain (kg) 10.67 ± 5.65 10.08 ± 5.61 0.048
Weight gain (%, kg)
  < 11.5
   11.5-16
  > 16
58.3
28.1
13.6
61.6
29.0
9.4
0.04
Parity (%)
   0
   1
  ≥ 2
42.1
37.4
20.6
49.1
38.8
12.0
< 0.001
Parity (No.)   0.85 ± 0.94   0.66 ± 0.80 < 0.01
Gestational age at delivery (week) 37.35 ± 2.94 37.85 ± 2.45 < 0.01
Hemoglobin A1C level (g/dL)   5.80 ± 0.89   6.03 ± 4.43 0.23
Education > 12 yr (%) 67.9 72.3 0.06
Preterm delivery (%) 24.8 18.0 < 0.01
Delivery mode-cesarean section (%) 58.4 58.1 0.89
Neonatal intensive care (%) 22.2 18.4 0.05
History of GDM (%) 10.2 11.1 0.54
Previous delivery of LGA baby (%) 5.7 5.3 0.72
Diabetes in first-degree relatives (%) 28.4 30.2 0.42
Preeclampsia (%) 6.9 4.8 0.047
Referral (%)
   Referral 
   for GDM treatment 
   for reasons other than GDM treatment
46.8
24.8
22.0
41.4
25.9
15.5
< 0.01
Pharmacotherapy for GDM (%) 28.6 46.8 < 0.01
BMI, body mass index; GDM, gestational diabetes mellitus; LGA, large for gestational 
age.
Table 2. Rates of adherence to postpartum glucose test according to risk factors
Non-compliant to 
postpartum test 
(n = 929)
Compliant to  
postpartum test 
(n = 757)
P value
No. of risk factors 0.289
   0 22.6 25.8
   1 43.2 40.0
  ≥ 2 34.2 34.1
Risk factors include pre-pregnancy obesity (body mass index ≥ 25 kg/m2), old age 
(age ≥ 35 yr), history of gestational diabetes mellitus, previous delivery of a large for 
gestational age baby, and history of diabetes in first-degree relatives.
Fig. 1. The rates of postpartum glucose screening among 4 centers.
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 The characteristics of the study participants are shown in Ta-
ble 1. Patients who were non-compliant to postpartum glucose 
testing had a higher parity and weight gain during pregnancy 
compared to women who were compliant to postpartum glu-
cose testing. The incidences of preterm birth and preeclampsia 
were higher in patients who were non-compliant to postpar-
tum glucose testing compared to women who were compliant 
to postpartum glucose testing. Patients who were non-compli-
ant to postpartum glucose testing were more likely to be referred 
from private clinics and less likely to have used pharmacother-
apy. However, other characteristics that were evaluated in this 
study were not different between the 2 groups.
 There were no differences in the risk factors that contributed 
to early screening between women who were and were not com-
pliant to screening (Table 2). Furthermore, there was no differ-
ence in the postpartum glucose testing rate among the 4 cen-
ters (P = 0.716, Fig. 1).
 We evaluated the factors related to postpartum glucose screen-
ing non-compliance by using multivariate logistic regression 
analysis. According to the multivariate analysis, patients with 
high parity, larger weight gain during pregnancy, and referral 
from private clinics due to reasons other than GDM treatment 
were less likely to receive postpartum glucose testing. However, 
patients with pharmacotherapy for GDM were more likely to be 
screened (Table 3). 
DISCUSSION
The postpartum glucose testing rate in this study was 44.9% (757/ 
1,686 patients), which is comparable to results from other stud-
ies (16). Several studies that were conducted to evaluate inde-
pendent factors related to postpartum glucose screening com-
pliance in various racial/ethnic cohort groups reported that the 
Asian group was associated with higher postpartum glucose 
screening rates (17,23,24). These rates (45%-85%) were higher 
than the rates from our study population which included only 
Asian participants. According to these results, the differences in 
screening rates may be due to the variations in how postpartum 
glucose screening was recommended by the health care pro-
viders to Asian women compared to other racial/ethnic groups 
and not based on the idea that Asians seek more healthcare 
given their higher prevalence of diabetes (27). 
 We identified factors associated with low postpartum glu-
cose screening testing rates. According to the results, patients 
who were transferred to the center due to reasons other than 
GDM treatment underwent less frequent postpartum glucose 
screening tests. Although the precise reason for this association 
was uncertain, it has been previously reported that women who 
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attended postpartum visits were more likely to complete post-
partum glucose screening (16,17,23,24,28). There is a high pos-
sibility of discontinuing antenatal and postpartum care in re-
ferred patients (i.e., referred and delivered at a tertiary center 
and then referred back to the private clinic after delivery) indi-
cating that referred patients may not attend postpartum visit. It 
is possible that these patients may have completed postpartum 
glucose screening at the private clinics, thereby did not return 
to the tertiary center for postpartum care. However, Russell et 
al. (17) reported that women attending postpartum visits at 
hospital-based clinics were twice as more likely to completing 
postpartum glucose testing compared to women at community 
clinics. Moreover, there is a high possibility of omitting postpar-
tum glucose screening at the private clinics due to physician’s 
limited access to the patient’s antenatal medical information 
regarding gestational diabetes or lack of vigilance (8). Therefore, 
these disturbances in medical care from the prenatal to post-
partum periods in referred patients may contribute to the low 
rates of postpartum glucose screening. GDM is associated with 
various maternal and fetal complications, such as preeclampsia 
and large for gestational age babies (7,8). Therefore, patients 
with GDM should be referred to tertiary centers for appropriate 
treatment where they should be informed regarding postpar-
tum glucose screening during pregnancy and provided remind-
ers for the screening tests (29). 
 Compatible to findings from other studies, patients who were 
non-compliant to postpartum glucose screening had higher 
parity (14,16,19,24) and were less likely to require insulin for 
glycemic control (16,19,20,24). Moreover, patients who were 
non-compliant to postpartum glucose screening had a higher 
weight gain during pregnancy. This may be a reflection of the 
“healthy cohort” effect where individuals who are more health-
conscious and made efforts to gain less weight during pregnan-
cy are more likely to seek treatment or follow-up (30). 
 It has been found in a previous study that a multidisciplinary 
team approach of caring for patients with DM resulted in large 
improvements in patient management (31). Similarly, Berg et 
al. (32) reported an improvement in GDM outcome by using a 
multidisciplinary team approach and Sempowski and Houlden 
(33) recommended referrals to multidisciplinary teams for in-
tensive glucose control for patients with GDM. It has been re-
ported that visits with an endocrinologist after delivery are as-
sociated with better screening rates (28). Although centers 1, 2, 
and 3 in this study implemented a multidisciplinary team with 
obstetricians, endocrinologist, and dieticians while center 4 in-
cluded only obstetricians, we did not observe any differences in 
postpartum glucose screening rates among these centers. Fur-
ther studies are needed to evaluate these unexpected results. 
 Out of 757 women who underwent postpartum glucose screen-
ing in this study, 18.4% patients had diabetes, which was higher 
compared to results from other studies. According to previous 
reports, the prevalence of diabetes ranged 1%-8% in Caucasians 
(14,16,17,24). In contrast, our results were comparable to results 
published by Jang et al. (34) who reported that approximately 
15.1% of 311 Korean women had diabetes. These discrepancies 
between studies may be partially due to the higher prevalence 
Table 3. Univariate and multivariate logistic regression analysis for non-compliance to postpartum glucose screening
Variables Unadjusted ORs (95% CI) P value Adjusted ORs* (95% CI) P value
Age (yr) 1.005 (0.982-1.029) 0.653 -
Pre-pregnancy BMI (kg/m2) 1.008 (0.986-1.031) 0.482 -
Weight gain (kg) 0.042 0.018
  < 11.5  1.024 (0.811-1.292) 0.992 (0.776-1.269)
   11.5-16 1 1
  > 16 1.534 (1.096-2.147) 1.661 (1.157-2.384)
Parity < 0.001 < 0.001
   0 1 1
   1 1.123 (0.910-1.386) 1.204 (0.949-1.528)
  ≥ 2 1.997 (1.498-2.661) 2.202 (1.600-3.031)
Education > 12 yr (yes) 0.812 (0.655-1.008) 0.059 0.783 (0.608-1.009) 0.059
Preterm delivery (yes) 1.500 (1.182-1.903) 0.001 1.326 (0.959-1.832) 0.088
Delivery mode: cesarean section (yes) 1.013 (0.834-1.231) 0.893 -
Neonatal intensive care (yes) 1.266 (0.996-1.611) 0.054 0.939 (0.677-1.301) 0.704
History of GDM (yes) 0.908 (0.66-1.241) 0.544 -
Previous delivery of LGA baby (yes) 1.082 (0.709-1.650) 0.715 -
Diabetes in first-degree relatives (yes) 0.916 (0.741-1.133) 0.419 -
Preeclampsia (yes) 1.482 (0.974-2.256) 0.067 1.011 (0.601-1.702) 0.967
Referral 0.003 0.014
   No referral 1 1
   For GDM treatment 1.054 (0.838-1.327) 1.261 (0.972-1.639)
   For reasons other than GDM treatment 1.567 (1.207-2.034) 1.516 (1.124-2.045)
Pharmacotherapy for GDM (yes) 0.456 (0.372-0.558) < 0.001 0.429 (0.340-0.542) < 0.001
*The model is adjusted for covariates that had statistical values of P less than 0.15 in the univariate analysis. OR, odds ratio; CI, confidence interval; BMI, body mass index; GDM, 
gestational diabetes mellitus; LGA, large for gestational age.
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of DM in the Asian population (35,36).
 Some limitations should be kept in mind when interpreting 
our findings. As our study was confined to medical chart review, 
we could not determine physician dependent factors including 
frequency of physician contact, use of reminder system and time 
spent on educating the consequences of GDM, which were as-
sociated with non-compliance to postpartum glucose testing. 
Further studies are needed to examine physician dependent 
factors for improvement of compliance to postpartum glucose 
testing. 
 In conclusion, 55.1% of patients with GDM failed to return to 
the tertiary center to complete postpartum glucose testing in 
this study. Considering the high prevalence of DM (18.4%) dur-
ing the postpartum period in our study population, it seems ur-
gently necessary to educate patients regarding the factors af-
fecting non-compliance and the importance of postpartum 
glucose testing. Furthermore, patients who are referred from 
other private clinics should be encouraged for postpartum glu-
cose testing and a collaborative strategy to enhance continuity 
of care and to alert patients of follow-up testing should be im-
plemented. 
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